Table 1.
Clinical trials for platinum-based chemotherapy in ovarian cancer
| Characteristic | Cancer | Treatment regimen | Patients enrolled | PFS(mo) | OS(mo) |
|---|---|---|---|---|---|
| Stage III and Stage IV [7] | Ovarian |
Cisplatin (75 mg per square meter of body-surface area) Cyclophosphamide (750 mg per square meter) |
202 | 13 | 24 |
|
Cisplatin (75 mg per square meter of body-surface area) Paclitaxel (135 mg per square meter over a period of 24 h). |
184 | 18 | 38 | ||
|
Stage III and Stage IV [8] |
Ovarian | Niraparib once daily after a response to platinum-based chemotherapy. | 487 | 13.9 | 84% (24-month interim analysis) |
| Placebo group once daily after a response to platinum-based chemotherapy | 246 | 8.2 | 77% (24-month interim analysis) | ||
|
Relapsed > 6 months following completion of platinum-based therapy [9] |
Ovarian and Primary Peritoneal Carcinoma | Cisplatin (60 mg/m2 IV) Flavopiridol (100 mg/m2 IV, 24 h infusion; 21 day cycles) | 40 | 4.3 | 16.1 |